<p>Researcher from New Jersey based Rutgers Cancer Institute found Immunotherapy may play an important role in treatment of thyroid cancer.</p><p>As reported by American Cancer society, there are several researches are come out to treat thyroid cancer in recent years in United States, as a result most of the thyroid cancer treated but some cases in which patient do not respond to Radio Active Iodine (RAI) therapy is difficult to treat and Immunotherapy play an important role to treat these difficulties.<br /><br /><br /><a href="http://www.srlchem.com/" target="_blank" rel="noopener noreferrer"><img src="http://www.microbiozindia.com/images/ASX.png" alt="" /></a></p><h2>According to Researcher,</h2><p>At the time our abstract was submitted, 22 patients with a diagnosis of advanced or metastatic papillary or follicular thyroid cancer who failed prior standard therapy were accrued from multiple international sites. Participants received 10 mg of pembrolizumab every two weeks for up to 24 months or until confirmed progression or unacceptable toxicity. Safety, tolerability and response were assessed every eight weeks for the first six months and every 12 weeks thereafter.</p><p><strong>Story source:</strong> Rutgers Cancer Institute of New Jersey.</p>